ACCOUNT

Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

PGe
NEWSLETTERS
PG STORE
ARCHIVES

CLASSIFIEDS

OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS

CONTACT US
ADVERTISING
CAREER OPPORTUNITIES

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.140 +0.040 (+3.64%)

Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

5 Cheapest Health Care Stocks You Should Think About ↗

January 27, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

ROSEN, LEADING INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE

January 26, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)

January 26, 2023

From Glancy Prongay & Murray LLP

Via Business Wire

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)

January 25, 2023

From Law Offices of Howard G. Smith

Via Business Wire

Analyst Ratings for Fate Therapeutics ↗

January 24, 2023

Via Benzinga

INVESTOR NOTICE: Fate Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Fate Therapeutics Class Action Lawsuit – FATE

January 25, 2023

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?

January 25, 2023

Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.

Via MarketBeat

Topics Workforce

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Fate Therapeutics, Inc. (FATE)

January 24, 2023

From Robbins LLP

Via Business Wire

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors

January 24, 2023

From The Law Offices of Frank R. Cruz

Via Business Wire

Bronstein, Gewirtz & Grossman, LLC Notifies Fate Therapeutics, Inc. (FATE) Investors of Class Action and to Actively Participate

January 24, 2023

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

January 24, 2023

From The Schall Law Firm

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023 ↗

January 24, 2023

Via Benzinga

FATE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc. and Encourages Investors to Contact the Firm

January 23, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors

January 23, 2023

From Glancy Prongay & Murray LLP

Via Business Wire

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors

January 23, 2023

From Kirby McInerney LLP

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Fate Therapeutics, Inc. (FATE) Investors

January 23, 2023

From Law Offices of Howard G. Smith

Via Business Wire

Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline

January 23, 2023

From Lowey Dannenberg, P.C.

Via GlobeNewswire

EQUITY ALERT: Rosen Law Firm Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FATE

January 23, 2023

From The Rosen Law Firm, P.A.

Via Business Wire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

January 23, 2023

From The Schall Law Firm

Via Business Wire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors

January 19, 2023

From Glancy Prongay & Murray LLP

Via Business Wire

5 Health Care Stocks That Are Diving - And May Rally ↗

January 19, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Bragar Eagel & Squire, P.C. Is Investigating Phathom, Super Micro, and Fate and Encourages Investors to Contact the Firm

January 18, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors

January 18, 2023

From Law Offices of Howard G. Smith

Via Business Wire

Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?

January 18, 2023

Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week.

Via MarketBeat

Topics Stocks

The Law Offices of Frank R. Cruz Continues Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors

January 17, 2023

From Law Offices of Frank R. Cruz

Via Business Wire

Over $10 Million Bet On DiamondHead Holdings? Check Out These 4 Stocks Insiders Are Buying ↗

January 17, 2023

Although US stocks closed higher on Friday, there were a few notable insider trades.

Via Benzinga

FATE ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Fate Stockholders and Encourages Investors to Contact the Firm

January 11, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors

January 11, 2023

From Glancy Prongay & Murray LLP

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors

January 11, 2023

From Law Offices of Howard G. Smith

Via Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of Fate Therapeutics, Inc. (FATE) on Behalf of Investors

January 11, 2023

From The Law Offices of Frank R. Cruz

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.